within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DH04_Doripenem;

model Doripenem_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.8611111111111113e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.0171,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.011699999999999999,
    k12 = 2.111111111111111e-06,
    k21 = 2.111111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Doripenem_1</td></tr><tr><td>ATC code:</td><td>J01DH04_1</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>17.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Doripenem is a carbapenem-class beta-lactam antibiotic used in the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia including ventilator-associated pneumonia. Approved for use in several countries, its marketing authorization has been withdrawn in some regions, but it is still available and used in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in patients with moderate renal impairment (creatinine clearance 30-50 mL/min) following intravenous infusion.</p><h4>References</h4><ol><li><p>Roberts, JA, et al., &amp; Lipman, J (2014). Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>The Journal of antimicrobial chemotherapy</i> 69(9) 2508–2516. DOI:<a href=\"https://doi.org/10.1093/jac/dku177\">10.1093/jac/dku177</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24879665/\">https://pubmed.ncbi.nlm.nih.gov/24879665</a></p></li><li><p>Lee, DH, et al., &amp; Kiem, S (2017). Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. <i>Antimicrobial agents and chemotherapy</i> 61(5) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02185-16\">10.1128/AAC.02185-16</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28223378/\">https://pubmed.ncbi.nlm.nih.gov/28223378</a></p></li><li><p>Wang, Y, et al., &amp; Zhang, J (2022). Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations. <i>Antibiotics (Basel, Switzerland)</i> 11(7) –. DOI:<a href=\"https://doi.org/10.3390/antibiotics11070958\">10.3390/antibiotics11070958</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35884212/\">https://pubmed.ncbi.nlm.nih.gov/35884212</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DH04_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Doripenem_1;
